UBRELVY is available in both 50 mg and 100 mg tablets1

  • Taken orally, with or without food
  • A second dose can be taken at least 2 hours after the initial dose (if needed)

  • The maximum daily dose is 200 mg
  • UBRELVY can be used to treat up to 8 migraines in a 30-day period
  • In a 1-year, long-term safety study with 21,454 migraine attacks treated, 88% of patients did not take rescue medication3,4

See study design page for more information.

UBRELVY 50 mg and 100 mg tablets and migraine treatment packagingTablets are not actual size.

Dosing Card

Dosing considerations1:

  • UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure
  • Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure
  • Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See section 2.2 of the Prescribing Information
  • Avoid use in patients with end-stage renal disease
  • Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice
  • Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose
  • In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline4
  • Low rates of rescue medication use were observed in the clinical trial program5*

*Rescue medication was the patient’s usual acute treatment for migraine.

References

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2020. 2. Ailani J, Blumenfeld AM, Klein B, et al. An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster P112. 3. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152. 4. Data on file. Allergan.5. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241.